The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Boston Scientific lifts its 2025 sales and EPS outlook after a strong Q1, with cardiology and EP segments fueling major gains.

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

Overall, the average yield on cost of my new investments in April averaged around 7.4%, reinforcing my belief in BDCs as a ...

From personal setbacks to professional leadership, McDowell advocates for smarter wound care and stronger ethics in medicine. NASHVILLE, TN / ACCESS Newswire / June 24, 2025 / In a recent exclusive ...

This was the stock's third consecutive day of gains.